Registration Dossier

Diss Factsheets

Administrative data

Description of key information

Guideline GLP acute toxicity studies are available for cloquintocet-mexyl technical (purity 91.6 or 96.7%) for the oral, inhalation and dermal routes of exposure. Data indicate that acute toxicity is expected to be low. Cloquintocet-mexyl  does not pose an acute hazard following oral (oral LD50 > 5000 mg/kg), skin contact (dermal LD50 > 2000 mg/kg) or acute inhalation (4 hour LC50 935 mg/m3) exposures and does not warrant classification for acute toxicity.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
Value:
5 000 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Dose descriptor:
LC50
Value:
935 mg/m³

Acute toxicity: via dermal route

Endpoint conclusion
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

Non-human information

Acute oral toxicity data for cloquintocet-mexyl indicate an oral LD50 value in rats of > 5000 mg/kg (Hartmann HR, 1987). The acute oral toxicity in mice is > 2000 mg/kg (Hartmann HR, 1991). A four hour acute inhalation toxicity study in rats showed no acute inhalation toxicity showed at the highest achievable concentration of 935 mg/m3 (Jackson GC, 1987). An acute dermal toxicity study gave an acute dermal LD50 value in rabbits of > 2000 mg/kg (Hartmann HR, 1987).  

Human information

There are no studies on the oral, inhalation or dermal toxicity in humans for cloquintocet-mexyl.

Justification for classification or non-classification

There are sufficient data on cloquintocet-mexyl to indicate that the substance is of low acute toxicity by the oral, dermal and inhalation routes and does not warrant classification for acute toxicity:

- under Directive 67/548/EEC, as amended for the 28th time in Directive 2001/59/EC, Annex VI, 3.2.

- under Regulation (EC) 1272/2008, Annex I, Part 3, 3.1.2.

Categories Display